LPA and acute coronary syndrome: A second subanalysis of the dal-Outcomes trial, including 4139 acute coronary syndrome patients treated with statins, did not show any association between Lp(a) concentrations and major adverse outcomes: for a doubling of the dose of Lp(a), the level of risk for CVD was stagnant (HR 1.01, 95% CI 0.96–1.06, P=0.66).9